Pharma and VC firms have a symbiotic relationship, with VCs providing crucial funding to startups, and pharmaceutical companies offering strategic partnerships and potential acquisition opportunities. How do they align their investment strategies to maximize mutual benefits? How do pharma and VC firms manage their differing risk appetites and investment timeframes? What approaches do pharma and VC firms take to due diligence and decision-making processes? What is the place for the corporate VCs in the relationship?
Moderator: Bart Wuurman, CEO, Apaxen